- EHV-2 is relatively inconsequential in Canada, although it is
ubiquitous throughout the world.
- Seroprevalence of
the virus ranges from 70-100%, with one study showing that 79.7% of
thoroughbreds had evidence of previous exposure to the virus.
- The rate
infection increases with age.
- The absolute role of EHV-2
causing disease is still unknown.
- Because it is so prevalent in the population,
it is found in the nasal passages of many healthy horses, as well as
horses that are showing clinical signs of respiratory disease. It has
suggested that the presence of EHV-2 in young foals predisposes them to
subsequent Rhodococcus equi
- EHV-2 has also been implicated in herd
- Because EHV-2 is present in
many healthy animals, there are no specific clinical signs that
infection with EHV-2.
- In clinical cases of conjunctivitis, affected horses
often experience photophobia, lacrimation, corneal color change and
ulceration. When EHV-2 has been associated with respiratory disease,
signs are coughing, pharyngeal ulceration, and lymphadenopathy.
- There is no vaccine
for EHV-2, and no specific preventative measures have been established.